Loading…
Based on limited metadata available, the FDA issued a Warning Letter to Episciences Inc. on August 25, 2022, regarding drug products. Without access to the full letter text or specific subject line details, the precise nature of the violations cannot be definitively characterized from this metadata alone. The warning falls under FDA's drug product regulatory authority, though the specific issuing office is not indicated in the available information. To understand the full scope and details of the compliance concerns, review of the complete Warning Letter would be necessary.